Semax vs Selank (2026): Nootropic Intranasal Peptides Compared

Semax and Selank are almost always discussed together, but their 2026 regulatory paths are no longer parallel. Semax sits on the July 24, 2026 Pharmacy Compounding Advisory Committee (PCAC) docket for cerebral ischemia, migraine, and trigeminal neuralgia. Selank’s 503A nomination was withdrawn by the nominator in September 2024 and there is no scheduled FDA review. Mechanistically the two peptides are also distinct: Semax (ACTH-derived) pushes the system toward higher monoaminergic and neurotrophin tone (stimulating, alerting); Selank (tuftsin-derived) pushes toward higher GABAergic tone without sedation (calming, smoothing). Both are administered intranasally and both are research peptides in the United States.

Table of Contents

• Quick Answer
• At a Glance Comparison
• Mechanism of Action
• Russian Clinical Evidence
• Western Evidence Base
• Dosing Protocols (Intranasal)
• When to Choose Which (or Both)
• Community Use Snapshot
• Combinations and Stacking Notes
• Side Effects and Safety
• Drug Interactions
• Cost and Access
• 2026 Regulatory Status
• Frequently Asked Questions
• References

Quick Answer

The 2026 headline is the regulatory asymmetry. Semax is on the FDA’s July 23-24, 2026 PCAC agenda (Day 2, July 24), under review for cerebral ischemia, migraine, and trigeminal neuralgia [1][2]. Selank’s 503A nomination was withdrawn by the nominator on or around September 20, 2024 (effective September 27, 2024) and Selank now sits in the FDA’s “Other Bulk Drug Substances That May Present Significant Safety Risks” holding category, with no scheduled review [3][4]. Most comparison pages still lump them together. They should not be lumped together regulatorily in 2026.

Mechanism distinction. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic ACTH(4-10) analog. It upregulates BDNF and NGF, activates dopaminergic and serotonergic tone, and produces a stimulant-like cognitive lift without engaging the HPA stress axis [5][6][7]. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic tuftsin analog. It modulates GABA-A receptor subunit gene expression (a positive-allosteric-modulator-like effect without direct receptor binding), inhibits enkephalinases, and produces anxiolysis without sedation [8][9][10]. The two peptides press on different parts of the system, which is why the stack works.

Both are research peptides in the US and approved prescription drugs in Russia. Semax has been approved since the 1990s (List of Vital and Essential Drugs, ischemic stroke and cognitive disorders) [6][11]; Selank was approved in 2009 for GAD and neurasthenia [9][12]. The Russian dossiers give both a longer post-marketing track record than typical research peptides, but Russian trial methodology often falls short of Western standards, and US FDA still treats both as investigational [13].

Both are administered intranasally, as drops or metered sprays at microgram doses. The math runs in micrograms per actuation, not milliliters of injection volume. PTK has dedicated intranasal calculator presets at /calculator/semax/ and /calculator/selank/.

At a Glance Comparison

Mechanism of Action: Same Heptapeptide Scaffold, Opposite Pharmacology

Both peptides share the same C-terminal Pro-Gly-Pro stabilizing tail but descend from completely different parent molecules. Semax descends from adrenocorticotropic hormone (ACTH), a pituitary stress hormone. Selank descends from tuftsin, a tetrapeptide cleaved from the Fc fragment of immunoglobulin G. That ancestry drives the divergent neurochemistry [5][6][8][9].

Semax (stimulating)

BDNF and NGF upregulation. Single-dose Semax increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the rat hippocampus, along with their TrkB receptors [7][14]. This is the molecular substrate for the neuroplasticity and cognitive-enhancement claims that drive community use, and Medvedeva et al. (2024) extended the finding to neurotrophin and neurotrophin-receptor gene transcription after experimental cerebral ischemia, underlying the Russian stroke-indication approvals [24].

Dopaminergic and serotonergic activation. Dolotov, Eremin, and colleagues (Neurochemical Research, 2006; PMID 16362768) showed single-dose Semax increases striatal 5-hydroxyindoleacetic acid (5-HIAA, the principal serotonin metabolite) by roughly 25% at 2 hours, with extracellular striatal 5-HIAA climbing to approximately 180% of baseline over 1 to 4 hours [15]. Comparable dopaminergic activation was observed. This produces the subjective stimulant-like effect.

No HPA axis activation. Unlike the parent ACTH molecule, Semax does not increase cortisol output. The added Pro-Gly-Pro tail strips away the steroidogenic activity while preserving the neurotropic activity [6], allowing chronic dosing without the cortisol-driven side-effect profile that limits ACTH itself.

Selank (anxiolytic)

GABAergic via gene expression, not direct binding. Volkova et al. (Frontiers in Pharmacology, 2017; PMID 26924987) demonstrated that Selank alters mRNA levels of GABA-A receptor subunits Gabrb3, Gabre, and Gabrq, plus the GABA transporter Slc6a13 (GAT-2) in rat frontal cortex [10][25]. The functional effect resembles a positive allosteric modulator of GABA-A (enhanced inhibitory tone) without the direct receptor agonism, sedation, amnesia, or muscle relaxation of benzodiazepines [10]. This is the published reason Selank produces anxiolysis without sedation.

Enkephalinase inhibition and monoamine normalization. Selank inhibits enzymes that degrade enkephalins, prolonging endogenous opioid signaling; serum enkephalin activity rises measurably [9]. Unlike Semax, Selank normalizes serotonin and dopamine around baseline rather than spiking them, contributing to the smoothing subjective profile [8][26].

Immunomodulation. Selank induces interferon-alpha gene expression and shifts the Th1/Th2 cytokine balance (Uchakina et al., 2008; PMID 18577961) [16], with documented antiviral activity against influenza A (H3N2) in cell culture and in mice (Mezentseva et al., 2009; PMID 19882898) [27].

Why they stack synergistically

Semax presses the system toward higher monoaminergic tone and neurotrophin output (alerting, focus, potentially edgy in anxiety-prone users). Selank presses the system toward higher GABAergic inhibitory tone and normalized monoamines (calming, smoothing, non-sedating). Co-administration produces what community users describe as “calm focus” (the alerting effect from Semax without the jitteriness or stress reactivity) [20][21]. There are no controlled clinical trials of the specific Semax-plus-Selank stack; the mechanistic case for combining them is biologically plausible but unconfirmed for any specific outcome.

Russian Clinical Evidence

Both peptides have substantially more clinical evidence than typical research peptides because both are approved drugs in Russia. The bulk of the data is in Russian-language journals (often Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova), with sample sizes in the 30 to 110 patient range. Methodology does not always meet contemporary Western standards: open-label or single-blind designs, limited central randomization, loosely specified primary endpoints, uncommon intention-to-treat analysis. Read as supportive evidence within the Russian regulatory framework, not as Western-RCT-grade confirmation [13].

Semax: stroke and cerebrovascular disease

Semax: attention disorders

Maslova et al. (2006; PMID 16996699) positioned Semax as a candidate for attention-deficit hyperactivity disorder and Rett syndrome, with mechanistic and small clinical pilot data showing improved attention span and reduced impulsivity in pediatric ADHD-equivalent cohorts on intranasal Semax dose-adjusted for age and weight [30]. Russian pediatric neurology literature has continued this line, though sample sizes remain small and replication outside Russia is essentially absent.

Selank: generalized anxiety disorder

The most-cited Selank human study is Zozulia, Neznamov, Siuniakov et al. (2008). 62 patients with generalized anxiety disorder and neurasthenia were randomized: 30 received intranasal Selank, 32 received medazepam (a benzodiazepine still in Russian formularies). Outcomes were assessed with the Hamilton Anxiety Rating Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression. Both treatments reduced anxiety to comparable extent; Selank produced less sedation, less cognitive impairment, an antiasthenic and mild psychostimulant effect, and no withdrawal on discontinuation [9]. Open-label by Western standards, modest sample size, but the head-to-head against an active benzodiazepine comparator is notable. Separately, Uchakina et al. (2008) documented Th1/Th2 cytokine shifts and Mezentseva et al. (2009) documented antiviral activity against influenza A (H3N2) via interferon-alpha induction [16][27].

Western Evidence Base

Both molecules have mechanistic and preclinical representation in Western peer-reviewed journals, but no Western-regulator-grade RCT exists for either Semax or Selank. Anyone citing “Western clinical evidence” for either is reaching.

Semax: Western and PubMed work

• Dolotov et al. (2006), Neurochemical Research: dopaminergic and serotonergic activation in rodents [15]
• Dolotov et al. (2006), Brain Research: BDNF and TrkB expression in rat hippocampus [14]
• Medvedeva et al. (2024): neurotrophin gene transcription after cerebral ischemia [24]
• MDPI Genes (2023) review of neuroprotective peptides for ischemic stroke (Semax featured in the broader synthesis) [31]

Selank: Western and PubMed work

• Volkova et al. (2017), Frontiers in Pharmacology: GABAergic gene-expression effects in IMR-32 cells and rat frontal cortex [10][25]
• Kolomin et al.: hippocampal and splenic transcriptomic response to single and chronic Selank [25]
• Inozemtseva et al. (multiple): behavioral and biochemical effects in rodent anxiety models

What the Western data does and does not show

The Western literature confirms the mechanisms described by Russian groups (BDNF and NGF upregulation, dopaminergic activation, GABA-A subunit mRNA modulation, immune modulation). What it does not provide is independent confirmation of clinical efficacy in stroke, anxiety, attention disorders, migraine, or any of the indications under FDA consideration. The FDA’s PCAC background packet on Semax, expected around July 21 to 22, 2026, will become the most important Western synthesis to date.

Dosing Protocols (Intranasal)

Both peptides are dosed in micrograms per intranasal actuation, not milligrams of injection volume. This is a different mental model than subcutaneous peptides like BPC-157 or tirzepatide. The PTK calculator presets at /calculator/semax/ and /calculator/selank/ handle the intranasal math for both peptides. N-acetylated variants (NA-Semax and N-acetyl Selank Amidate, “NASA Selank”) are more metabolically stable analogs increasingly used by the community.

Semax intranasal dosing

Selank intranasal dosing

Cycling and PTK calculator integration

Both peptides are typically cycled 2 to 4 weeks on, 2 weeks off, with the stated rationale of preserving receptor sensitivity and periodically reassessing baseline cognition and anxiety [20][21]. There is no controlled-trial evidence that on-off cycling is necessary; it is a community convention. The PTK calculator’s intranasal presets read out per-spray and total-daily-microgram results for any reconstitution concentration. Plan with the calculator first; do not eyeball drops or sprays.

When to Choose Which (or Both)

The default community pattern is to use both. If a single-agent choice is forced (cost, side-effect concern, ingredient access), the considerations break down as follows.

The stack pattern. The most common community stack is Semax 200 to 400 mcg plus Selank 200 to 400 mcg intranasally in the morning, optionally with a smaller afternoon dose taken no later than 2 to 3 pm to avoid sleep interference from Semax [20][21][36]. The combination is described as producing cognitive sharpness from Semax without the edginess that some users report from Semax monotherapy, while Selank’s slight pro-cognitive effect compounds with Semax rather than dragging it down. There are no clinical trials of the stack; the protocol exists in community practice and mechanistic reasoning [20][21].

Community Use Snapshot

Community use clusters on three patterns. Solo Semax for cognitive work blocks (300 to 600 mcg AM, optionally midday). Solo Selank for high-anxiety windows (250 to 500 mcg as needed or daily for 2-week courses). The Semax-plus-Selank stack (200 to 400 mcg each, AM with optional early-afternoon dose) is the most popular pattern overall, reported as producing “calm focus” without the edginess of Semax monotherapy [20][21][22][36]. Users typically describe Selank as more subtle than Semax, with smaller per-dose effect but more sustained. NA-Semax and NASA Selank variants are used identically to the parent peptides, often at 50 to 75% of the dose because of stronger per-microgram reports [20][34]. None of this is clinically validated; it is community pattern.

Combinations and Stacking Notes

Semax plus Selank is itself the canonical nootropic stack in this category. The mechanistic basis (BDNF and NGF upregulation plus monoaminergic activation paired with GABA-A subunit modulation plus monoamine normalization) is biologically plausible and aligns with the community-reported “calm focus” profile [7][10][14][15]. There are no controlled clinical trials of the specific stack; the application is reasoned from preclinical pharmacology, not measured in an RCT.

Community protocols sometimes add other peptides to a Semax-plus-Selank cycle. BPC-157 for soft-tissue healing (independent angiogenesis mechanism, no controlled stack trial). Epitalon in longevity-oriented stacks for sleep architecture and telomere effects (no controlled stack data). Modafinil, caffeine, or stimulants with Semax produce additive monoaminergic load, especially risky in anxiety-prone or cardiovascular-risk users. Benzodiazepines, alcohol, or gabapentinoids with Selank produce additive GABAergic effects; the additive sedation and disinhibition risk is the relevant concern even though Selank itself is non-sedating [22].

Side Effects and Safety

Both Semax and Selank have unusually clean safety profiles in the published Russian datasets: no sedation, no cognitive impairment, no withdrawal, no abuse potential, and no major long-term adverse events documented across decades of prescription use. The realistic risk picture is dominated by short-term local effects (nasal irritation, headache) plus a real gap in formal Western long-term toxicology (carcinogenicity, mutagenicity, and reproductive toxicity studies have not been conducted to FDA standards for either peptide) [37][38].

Semax side effects

• Most common: Transient nasal irritation, mild headache, occasional dysgeusia (metallic taste) during or shortly after administration [37]
• Approximately 10% in Russian prescribing info: Visible changes in nasal mucosa (discoloration) with prolonged use [37]
• Diabetic users: Russian clinical data has documented small increases in blood glucose [37]
• Not observed: Sedation, respiratory depression, dependence, withdrawal, even at the 18 mg/day stroke dose [37]

Selank side effects

• Most common: Mild nasal irritation, occasional mild headache. Side-effect rates lower than Semax in published data [38]
• Headline differentiator vs benzodiazepines: No sedation, no cognitive impairment, no withdrawal, no tolerance, no abuse potential [9][38]
• No serious adverse events in published Russian trials [9][38]

Long-term safety gap (both)

Neither Semax nor Selank has had carcinogenicity, mutagenicity, or reproductive toxicity studies conducted to FDA standards [37][38]. The “decades of safe use in Russia” line is real but is not a substitute for formal long-term toxicology. There is no FDA black box warning attached to either peptide because neither is FDA-approved; absence of a warning is not a safety endorsement, it is a regulatory non-event.

Drug Interactions

Semax has additive monoaminergic effect with stimulants (amphetamines, modafinil) and SSRIs / SNRIs. Theoretical serotonin syndrome risk exists at very high combined serotonergic loads; no case reports in the Russian literature, but the mechanism is plausible enough to flag. Selank has additive GABAergic effects with benzodiazepines, alcohol, z-drugs, and gabapentinoids; the additive sedation and disinhibition risk is the relevant concern even though Selank itself is non-sedating. The interaction with serotonergic and dopaminergic agents via Selank’s secondary monoamine-normalization effect is clinically minor. See the PTK peptide interactions reference.

Cost and Access

Both are available through the US research-peptide market in 2026, with standard caveats about purity, identity testing, and lack of FDA oversight. Neither is dispensable through a 503A compounding pharmacy for human use. The 2026 outlook diverges sharply between the two (see Regulatory Status below).

Per PTK editorial policy, we do not link to research-peptide suppliers. Identity, purity, and bacterial endotoxin testing are inconsistent across this market, and none of these vendors are FDA-licensed pharmacies. Imported personal-use pharmaceutical-grade Russian product is the most “official” channel in terms of product quality but US import legality is unclear and is not a recommendation. The PTK bacteriostatic water guide and reconstitution resources cover the supplies side without endorsing research-peptide vendors.

2026 Regulatory Status

The 2026 regulatory pictures for Semax and Selank are sharply divergent. This is the single most important update relative to any pre-2026 comparison of these two peptides, and it is the section where most competitor pages are stale.

Three regulatory threads (do not conflate)

Three FDA regulatory threads run in parallel in 2026 and are routinely conflated. Thread 1 (CJC-1295 / Ipamorelin / AOD-9604 / Thymosin Alpha-1 / Selank): already decided. Removed from Category 2 in September 2024 via nominator withdrawals; PCAC voted against 503A inclusion of CJC-1295 and Ipamorelin in late 2024; Selank’s withdrawal removed it from PCAC review entirely [3][4][17]. Thread 2 (April 2026 12-peptide removal, July 2026 PCAC): a different batch. On April 15, 2026 (Federal Register 91 FR 20465, effective April 22), FDA removed 12 peptides from Category 2 and scheduled PCAC for July 23-24 [1][2][39]. The seven peptides on the agenda are Day 1 (July 23): BPC-157, KPV, TB-500, MOTs-C; Day 2 (July 24): Emideltide (DSIP), Semax, Epitalon [1][2]. Selank is not on this list. Thread 3 (GLP-1 503B exclusion): different drug class. The April 30, 2026 FDA proposed rule excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list applies to GLP-1s only and does not apply to Semax or Selank [39].

Semax: under active PCAC review July 24, 2026

Indications under review: Cerebral ischemia, migraine, trigeminal neuralgia [1][2]. Possible outcomes: (a) PCAC recommends inclusion and FDA can move Semax to Category 1 (enforcement discretion, most permissive); (b) PCAC recommends against and FDA returns Semax to Category 2 or leaves it in the gray zone; (c) split recommendation by indication. Recommendations are advisory and non-binding but historically influence FDA action [17][39].

Selank: nomination withdrawn, no scheduled review

Practical effect: There is no FDA-sanctioned US compounding pathway for Selank as of June 2026. US 503A compounding pharmacies cannot legally dispense Selank for human use. Supply is limited to the research-peptide market (outside FDA’s compounding framework entirely) or imported personal-use product from countries where it is approved (Russia, possibly Ukraine) [4][40].

Russia approval status (both)

Semax has been approved in Russia since the 1990s for ischemic stroke and cognitive disorders (0.1% nootropic and 1% prescription stroke products; on Russia’s List of Vital and Essential Drugs) [6][11]. Selank was approved in Russia in 2009 for GAD and neurasthenia as a 0.15% prescription intranasal spray [9][12]. These approvals are irrelevant to US compounding law but matter for the framing that these are not typical research peptides; they are approved drugs somewhere.

WADA 2026 status

Neither Semax nor Selank is explicitly named on the WADA 2026 Prohibited List [18][19]. Both face exposure under WADA’s catch-all clauses: S0 (any substance not approved by a governmental regulatory health authority for human therapeutic use), where Russian approval may or may not satisfy WADA, and S2 (“any other substance with a similar chemical structure or similar biological effect” to listed peptide hormones and growth factors), where Semax’s BDNF and NGF modulation has been cited as fitting [18][19]. Practical guidance: both peptides should be treated as prohibited until an athlete obtains a specific TUE or written WADA / USADA clearance.

Frequently Asked Questions

What is the difference between Semax and Selank?

Semax is a synthetic ACTH(4-10) analog (MEHFPGP) that upregulates BDNF and NGF and activates dopaminergic / serotonergic tone (stimulant-like cognitive lift). Selank is a synthetic tuftsin analog (TKPRPGP) that modulates GABA-A subunit gene expression and inhibits enkephalinases (anxiolysis without sedation). Both are intranasal Russian-developed heptapeptides with opposite neurochemistry [5][6][7][8][9][10].

Can I use them together?

Yes; the stack is the most common community pattern. Mechanistically the two peptides press different parts of the system (monoaminergic up plus GABAergic up plus monoamine normalization), and users describe the combination as “calm focus.” There are no controlled trials. Standard community dosing is 200 to 400 mcg of each intranasally in the morning, with an optional smaller afternoon dose [20][21][22][36].

Are Semax and Selank FDA-approved?

No. Neither has FDA approval for any indication. Both are approved as prescription nasal sprays in Russia (Semax in the 1990s for ischemic stroke and cognitive disorders; Selank in 2009 for GAD and neurasthenia), but US FDA treats both as investigational. Semax is under PCAC review for the 503A bulks list with a vote July 24, 2026; Selank’s 503A nomination was withdrawn in September 2024 with no scheduled review [1][2][3][4][6][9].

What does the July 2026 PCAC review mean for Semax?

On July 24, 2026 (Day 2 of the two-day meeting), PCAC will recommend whether FDA should add Semax to the 503A bulks list for compounding under the indications of cerebral ischemia, migraine, and trigeminal neuralgia [1][2]. A favorable vote could open 503A compounding within months; an unfavorable vote returns Semax to Category 2 or the current gray zone. The recommendation is advisory and non-binding but historically influences FDA action. FDA background materials, typically posted around July 22, 2026, will be the most important Western synthesis of the Semax evidence base to date [1][2][17].

Why was Selank’s 503A nomination withdrawn?

Selank acetate (TP-7) had been nominated for the 503A bulks list and sat in Category 2. On or around September 20, 2024, the nominator withdrew the nomination, and FDA removed Selank from Category 2 effective September 27, 2024 [3][4]. The nominator’s identity and rationale are not in the public record we could surface to primary-source standard. The practical effect: Selank no longer has an active 503A pathway, no PCAC review is scheduled, and US compounding pharmacies cannot legally dispense Selank for human use [4][40].

How do I dose intranasal peptides?

Intranasal peptides are dosed in micrograms per spray or per drop, not milligrams of injection volume. The math depends on vial size (mg), reconstitution volume (mL), and volume per actuation. A 10 mg Semax vial reconstituted in 3 mL yields ~3.3 mg/mL, and a typical metered nasal spray delivers ~100 microliters per actuation, giving ~333 mcg per spray. Use the PTK calculator presets at /calculator/semax/ and /calculator/selank/ to dial in your specific reconstitution.

Bottom Line

Semax and Selank are mechanistically opposite Russian-developed intranasal heptapeptides on sharply divergent US regulatory paths in 2026. Semax (ACTH-derived, stimulating, BDNF / NGF up, monoaminergic activating) is under PCAC review July 24, 2026 for cerebral ischemia, migraine, and trigeminal neuralgia. Selank (tuftsin-derived, anxiolytic without sedation, GABAergic-via-gene-expression) had its 503A nomination withdrawn in September 2024 with no scheduled review. The community “calm focus” stack of both is the dominant use pattern.

If forced to one peptide, Semax favors cognitive performance and post-ischemic / migraine adjunct; Selank favors anxiety reduction without sedation. Most people are not choosing between them; they are deciding whether to stack both. Plan reconstitution with the PTK Semax calculator and PTK Selank calculator; read the deeper Semax guide and Selank guide for protocol detail.

Read Next

• Semax: full protocol guide
• Selank: anxiolytic mechanism and dosing
• Reconstitution beginner guide
• Peptide and drug interactions checker
• Our editorial methodology

References

1. FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Advisory Committee Calendar. fda.gov.
2. Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 91 FR 20465. Docket No. FDA-2025-N-6895. Published April 16, 2026. federalregister.gov.
3. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Selank acetate / TP-7 removed from Category 2 effective September 27, 2024 following nominator withdrawal). fda.gov.
4. Lexology. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review (covers September 2024 Selank withdrawal and April 2026 12-peptide removal). lexology.com.
5. PeptideDB / PubChem. Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP). peptide-db.com.
6. Peptide Initiative. How Semax Works: ACTH Analog Mechanism. peptideinitiative.com.
7. Alzheimer’s Drug Discovery Foundation. Semax: Cognitive Vitality For Researchers (briefing PDF; BDNF and NGF mechanism review). alzdiscovery.org.
8. Biotech Peptides. From Tuftsin to Selank: Exploring the Synthetic Heptapeptide (Selank sequence TKPRPGP, origin and mechanism). biotechpeptides.com.
9. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. researchgate.net.
10. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2017. PMID: 26924987. frontiersin.org.
11. Gusev EI, Skvortsova VI, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997. PMID: 11517472. pubmed.ncbi.nlm.nih.gov.
12. Selank: Wikipedia overview (cross-referenced to primary literature, treated as secondary aggregator; Russia 2009 GAD approval). wikipedia.org.
13. HealingMaps. Semax: The Russian Nootropic Peptide Under FDA Review for Stroke and Migraine (Russian regulatory framing and 2026 PCAC context). healingmaps.com.
14. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. sciencedirect.com.
15. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. Neurochemical Research. 2005/2006. PMID: 16362768. pubmed.ncbi.nlm.nih.gov.
16. Uchakina ON, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. 2008. PMID: 18577961. pubmed.ncbi.nlm.nih.gov.
17. Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings (April 2026 timing and effective dates). orrick.com.
18. WADA. International Standard Prohibited List 2026 (Sections S0 and S2 catch-all language). wada-ama.org.
19. USADA. Athlete Advisory: What’s New on the 2026 WADA Prohibited List? usada.org.
20. Peptides.org. Semax Dosage Calculator and Chart (community dosing ranges and N-acetyl variant discussion). peptides.org.
21. PeptideWiki. Semax Dosage Guide (cognitive-protocol community dose ranges and cycling). peptidewiki.co.
22. Peptides.org. N-Acetyl Selank Amidate Dosage Calculator and Chart (Selank community dosing including 2,700 mcg/day clinical maximum). peptides.org.
23. KlearMind Clinics. Selank Dosing Guide: Dosage, Protocol, Safety and Charts. klearmindclinics.com.
24. Medvedeva EV, et al. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. PMC archived. pmc.ncbi.nlm.nih.gov.
25. Kolomin T, et al. Transcriptomic Response of Rat Hippocampus and Spleen Cells to Single and Chronic Administration of the Peptide Selank (ResearchGate / PubMed hosted; supports GABA-A subunit and immune gene findings).
26. Source Peptides. Selank Peptide Research Guide: Mechanisms, Cognitive Studies and Anxiolytic Properties (Selank monoamine normalization framing). sourcepeptides.co.
27. Mezentseva MV, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. 2009. PMID: 19882898. pubmed.ncbi.nlm.nih.gov.
28. Gusev EI, Skvortsova VI, et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. 2005. PMID: 15792140. pubmed.ncbi.nlm.nih.gov.
29. ResearchGate. The efficacy of semax in the treatment of patients at different stages of ischemic stroke (110-patient BDNF-recovery cohort). researchgate.net.
30. Maslova MV, et al. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. 2006. PMID: 16996699. pubmed.ncbi.nlm.nih.gov.
31. MDPI Genes. Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries. 2023. mdpi.com.
32. ParaHealth. Semax Dosing Guide: Intranasal Research Protocols (0.3% reconstitution target and metered actuation math). parahealth.com.
33. Peptides.org. Selank dosing and Russian 0.15% intranasal product reference. peptides.org.
34. PeptideDeck. N-Acetyl Selank (NASA Selank): Complete Research Guide. peptidedeck.com.
35. Peptide Ed Hub. NA-Selank: Enhanced Anxiolytic Peptide (community dosing for the amidated variant). pepedhub.com.
36. FormBlends. The Nootropic Peptide Stack: Semax, Selank, and Cognitive Peptide Protocols (community stack pattern). formblends.com.
37. Peptides.org. Semax Side Effects: Clinical Data, Safety, and Risks. peptides.org.
38. Peptides.org. Selank Side Effects: Clinical Data, Safety, and Risks. peptides.org.
39. Frier Levitt. FDA Peptide Update 2026: Removal from “Do Not Compound” List (covers both September 2024 and April 2026 removals and Selank pathway commentary). frierlevitt.com.
40. Newtropin. Semax FDA Status 2026: Is This Cognitive Peptide Heading to Legal Compounding? (also covers Selank pathway after September 2024 withdrawal). newtropin.com.